Evidence map›Paper›PMID 33718791›Full record

ReviewMayo Clinic proceedings. Innovations, quality & outcomes2021

Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials.

Khaled M Nada, Shawn Nishi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Mayo Clinic proceedings. Innovations, quality & outcomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Khaled M NadaDepartment of Internal Medicine, Division of Pulmonary Critical Care & Sleep Medicine, The University of Texas Medical Branch, Galveston, TX.
Shawn NishiDepartment of Internal Medicine, Division of Pulmonary Critical Care & Sleep Medicine, The University of Texas Medical Branch, Galveston, TX.
The University of Texas Medical Branch at Galveston · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endoscopic lung volume reduction is now included in the guidelines for treatment in severe chronic obstructive pulmonary disease. Since December 2018, 2 valve systems have been approved by the US Food and Drug Administration (FDA). To date, there is no head-to-head trial comparing both valve systems and no clear benefit of one over the other. This article provides an overview of the two largest prospective trials performed with the FDA-approved valve systems.

Indexed as

COPD, chronic obstructive pulmonary diseaseCT, computed tomographyELVR, endoscopic lung volume reductionEMPROVE, Evaluation of the Spiration Valve System for Emphysema to Improve Lung FunctionFDA, US Food and Drug AdministrationFEV1, expiratory volume in 1 secondLIBERATE, Lung Function Improvement After Bronchoscopic Lung Volume Reduction With Pulmonx Endobronchial Valves Used in Treatment of EmphysemaLVRS, lung volume reduction surgeryMCID, minimal clinically important differenceNETT, National Emphysema Treatment TrialRV, residual volumeSOC, standard of careTLC, total lung capacityTLVR, target lung volume reduction

Identifiers

PMID33718791
PMCPMC7930786
OpenAlexW3111661447

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.